ClinicalTrials.gg
TerminatedNCT04747470Updated Sep 3, 2024Results posted

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GS-3583 and Zimberelimab in Advanced Solid Tumors, sponsored by Gilead Sciences. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule, GS-3583.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is planned to be conducted in 2 parts: Part 1: Dose Escalation and Part 2: Safety Run-In and Randomized Expansion.

The primary objectives of Part 1 are 1) To characterize the safety and tolerability of GS-3583 as monotherapy in participants with advanced solid tumors. 2) To determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of GS-3583 as monotherapy in participants with advanced solid tumors.

The primary objectives of Part 2 is to assess the safety and tolerability and to determine the RP2D of GS-3583 in combination with zimberelimab (ZIM) and platinum (cisplatin or carboplatin) + 5-fluorouracil (5-FU) chemotherapy in participants with head and neck squamous cell carcinoma (HNSCC) (Cohort A) or in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) (Cohort B).

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed locally advanced or malignant solid tumor that is to or intolerant of standard therapy or for which no standard therapy is available
  • Have on imaging based on Version 1.1 (RECIST 1.1)
  • (ECOG) performance status of ≤ 2
  • of ≥ 3 months, in the opinion of the investigator
  • Adequate organ function as assessed by hematological, renal, and hepatic parameters, and no coagulopathy

Key Exclusion Criteria:

  • Received prior systemic cytotoxic chemotherapy, biological therapy, radiotherapy, or major surgery within 3 weeks of Cycle 1 Day 1; a 1-week is permitted for palliative radiation to non-central nervous system (CNS) disease with sponsor approval
  • Known severe reactions ( Grade ≥ 3) to fully human monoclonal antibodies or fusion proteins, GS-3583 formulation , or severe reaction to immuno-oncology agents, such as colitis or pneumonitis requiring treatment with , any history of anaphylaxis, or uncontrolled asthma
  • Concurrent active other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer who has undergone potentially curative therapy with no evidence of disease. Individuals with other previous malignancies are eligible if disease free for > 2 years.
  • Previous history of hematological malignancy, monoclonal gammopathy of unknown significance (MGUS) or other preleukemic states (Presence of clonal hematopoiesis of indeterminate potential (CHIP)/age related clonal hematopoiesis (ARCH) is acceptable)
  • Known (es), unless metastases are treated and stable and the individual does not require systemic corticosteroids for management of CNS symptoms at least 1 week prior to study treatment. Individuals with history of carcinomatous meningitis are excluded regardless of clinical stability.
  • Active or history of disease that has required systemic treatment within 2 years of the start of study treatment (ie, with use of disease-modifying agents, corticosteroids, or drugs)

    • Note: Individuals with diabetes type 1, vitiligo, psoriasis, hypothyroid disease, or hyperthyroid disease, not requiring immunosuppressive treatment are eligible.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1: GS-3583 675 μg

    Participants with advanced solid tumors will receive GS-3583 675 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.

    Drug: GS-3583

  • Experimental
    Part 1: Cohort 2: GS-3583 2000 μg

    Participants with advanced solid tumors will receive GS-3583 2000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.

    Drug: GS-3583

  • Experimental
    Part 1: Cohort 3: GS-3583 6000 μg

    Participants with advanced solid tumors will receive GS-3583 6000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.

    Drug: GS-3583

  • Experimental
    Part 1: Cohort 4: GS-3583 12000 μg

    Participants with advanced solid tumors will receive GS-3583 12000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.

    Drug: GS-3583

  • Experimental
    Part 1: Cohort 5: GS-3583 20000 μg

    Participants with advanced solid tumors will receive GS-3583 20000 μg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for up to 13 cycles (up to 52 weeks) or until the participant met study treatment discontinuation criteria.

    Drug: GS-3583

  • Experimental
    Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy

    Participants with head and neck squamous cell carcinoma (HNSCC) will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under the curve 5 mg/mL/min on Day 1 of each 28- day cycle up to 6 cycles + 5-5-flourouracil (5-FU) 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.

    Drug: GS-3583 · Drug: Zimberelimab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy

    Participants with non-small cell lung cancer (NSCLC) will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.

    Drug: GS-3583 · Drug: Docetaxel

  • Experimental
    Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy

    Participants with HNSCC will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under the curve 5 mg/mL/min on Day 1 of each 21-day cycle up to 6 cycles + 5-FU 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.

    Drug: GS-3583 · Drug: Zimberelimab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy

    Participants with HNSCC will receive ZIM 360 mg, on Day 1 of each 21-day cycle up to 105 weeks + cisplatin 100 mg/m\^2 of BSA on Day 1 of each 21-day cycle up to 6 cycles + carboplatin area under th e curve 5 mg/mL/min on Day 1 of each 21-day cycle up to 6 cycles + 5-FU 1000 mg/m\^2 of BSA/day on Days 1 to 4 of 21-day cycle up to 6 cycles.

    Drug: Zimberelimab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy

    Participants with NSCLC will receive GS-3583 at a dose determined in Part 1 on Day 1 of every 21-day cycles for up to 8 cycles + docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.

    Drug: GS-3583 · Drug: Docetaxel

  • Experimental
    Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy

    Participants with NSCLC will receive docetaxel 75 mg/m\^2 on Day 1 of each 21-day cycle until 1 or more criteria for discontinuation are met.

    Drug: Docetaxel

Interventions

  • DrugGS-3583

    Administered as an intravenous (IV) infusion

  • Administered as an IV infusion

  • Administered as an IV infusion

  • Administered as an IV infusion

  • Administered as an IV infusion

  • Administered as an IV infusion

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)

    DLT was defined as any toxicity (hematologic, non-hematologic, dosing/procedures-related toxicities, or grade 5 event (ie death)) occurring with GS-3583 monotherapy during the DLT assessment period (from Day 1 up to Day 28) considered at least possibly related to GS-3583 monotherapy.

    Time frame: Part 1: Day 1 through Day 28; Part 2: Day 1 through Day 21

  2. Parts 1 and 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    TEAEs were AEs with onset dates on or after the first dose and up to 90 days after the date of the last dose of study treatment or the day before initiation of subsequent therapy, whichever occurred first. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.

    Time frame: First dose date up to last dose date plus 90 days (Up to 4 months)

  3. Parts 1 and 2: Percentage of Participants With Laboratory Abnormalities According to the NCI CTCAE Version 5.0

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time, up to 90 days after the last dose of study drug or the day before initiation of subsequent therapy, whichever occurred first. A treatment-emergent laboratory abnormality severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.

    Time frame: First dose date up to last dose date plus 90 days (Up to 4 months)

  4. Parts 1 and 2: Percentage of Participants With GS-3583 Anti-drug Antibodies (ADAs) at Any Visit

    Participants were monitored for the development of ADAs throughout their treatment period with GS-3583 and at the end of study.

    Time frame: Cycles 1and 3,pre-dose,End of Infusion (EOI);2,6 hours;Days 2,3,5,8,15 post Day 1EOI;Day 15:Cycle 1:predose and EOI;2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI(Cycle length = 28 days in Part 1; 21 days for Part 2;infusion duration=60 minutes)

Secondary outcomes

  1. Part 1: Pharmacokinetic (PK) Parameter: AUCtau of GS-3583

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval where tau = 15 days.

    Time frame: Cycles 1 and 3, pre-dose, EOI; 2, 6 hours; Days 2, 3, 5, 8, 15 post Day 1 EOI; Day 15:Cycle 1:predose and EOI; 2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1; Infusion duration=60 minutes)

  2. Part 1: PK Parameter: Cmax of GS-3583

    Cmax is defined as the maximum observed plasma concentration.

    Time frame: Cycles 1 and 3,pre-dose,EOI;2, 6 hours;Days 2, 3, 5, 8, 15 post Day 1 EOI;Day 15:Cycle 1:predose and EOI;2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1;Infusion duration=60 minutes)

  3. Part 1: PK Parameter: Tmax of GS-3583

    Tmax is defined as the time to reach maximum observed plasma concentration (Tmax).

    Time frame: Cycles 1 and 3, pre-dose, EOI; 2, 6 hours; Days 2, 3, 5, 8, 15 post Day 1 EOI; Day 15:Cycle 1:predose and EOI; 2 hours post EOI; Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1; infusion duration=60 minutes)

  4. Part 2: Confirmed Objective Response Rate (ORR)

    Confirmed ORR is defined as the percentage of participants who have achieved confirmed CR or PR according to RECIST V1.1 and assessed by the investigator. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)

  5. Part 2: Progression-free Survival (PFS)

    PFS is defined as the time from first dose date until first date of disease progression (PD) or death from any cause, whichever comes first as measured per RECIST V1.1 as assessed by the investigator. Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)

  6. Part 2: Duration of Response (DOR)

    DOR was defined as time of first response (CR or PR) per RECIST V1.1 as assessed by the investigator until the date of first documented disease progression or death, whichever comes first. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)

  7. Part 2: Overall Survival (OS)

    Overall survival is defined as the time from randomization until death from any cause.

    Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)

  8. Part 2: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with a best overall confirmed response of CR or PR or stable disease. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: First dose date in Part 2 to End of Study (approximately 4.2 months)

  9. Part 2: PK Parameters: Cmax for GS-3583

    Cmax is defined as the maximum observed serum concentration of drug.

    Time frame: Safety-run In:Cycles 1 and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, 15; Part 2 all arms:Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 60-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)

  10. Part 2: PK Parameter: Tmax for GS-3583

    Tmax is defined as the time (observed time point) of the occurrence of Cmax.

    Time frame: Safety-run In: Cycles 1, and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, Day 15; Part 2: all arms: Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 6-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)

  11. Part 2: PK Parameter: AUCtau of GS-3583

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval.

    Time frame: Safety-run In: Cycles 1, and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, Day 15; Part 2: all arms: Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 6-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)

07

Results

Posted Sep 3, 2024

Participant flow

Participants were enrolled at study sites in the United States. This study was planned to be conducted in 2 parts: Part 1: Dose Escalation Part and Part 2: Safety Run-In and Randomized Expansion Part. Due to early termination of the study, Part 2 was not conducted. Results are reported only for Part 1 of the study.

Participant flow — Overall Study
MilestonePart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
Started03334000000
Completed00000000000
Not completed03334000000
Withdrew: Death03222000000
Withdrew: Withdrew consent00010000000
Withdrew: Study terminated by sponsor00102000000

Outcome measures

PrimaryParts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)

DLT was defined as any toxicity (hematologic, non-hematologic, dosing/procedures-related toxicities, or grade 5 event (ie death)) occurring with GS-3583 monotherapy during the DLT assessment period (from Day 1 up to Day 28) considered at least possibly related to GS-3583 monotherapy.

Time frame:
Part 1: Day 1 through Day 28; Part 2: Day 1 through Day 21
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
percentage of participantsPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
Parts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)—0000——————
PrimaryParts 1 and 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

TEAEs were AEs with onset dates on or after the first dose and up to 90 days after the date of the last dose of study treatment or the day before initiation of subsequent therapy, whichever occurred first. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.

Time frame:
First dose date up to last dose date plus 90 days (Up to 4 months)
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
percentage of participantsPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
Parts 1 and 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0—100100100100——————
PrimaryParts 1 and 2: Percentage of Participants With Laboratory Abnormalities According to the NCI CTCAE Version 5.0

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time, up to 90 days after the last dose of study drug or the day before initiation of subsequent therapy, whichever occurred first. A treatment-emergent laboratory abnormality severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.

Time frame:
First dose date up to last dose date plus 90 days (Up to 4 months)
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Laboratory Abnormalities According to the NCI CTCAE Version 5.0
percentage of participantsPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
Parts 1 and 2: Percentage of Participants With Laboratory Abnormalities According to the NCI CTCAE Version 5.0—100100100100——————
PrimaryParts 1 and 2: Percentage of Participants With GS-3583 Anti-drug Antibodies (ADAs) at Any Visit

Participants were monitored for the development of ADAs throughout their treatment period with GS-3583 and at the end of study.

Time frame:
Cycles 1and 3,pre-dose,End of Infusion (EOI);2,6 hours;Days 2,3,5,8,15 post Day 1EOI;Day 15:Cycle 1:predose and EOI;2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI(Cycle length = 28 days in Part 1; 21 days for Part 2;infusion duration=60 minutes)
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With GS-3583 Anti-drug Antibodies (ADAs) at Any Visit
percentage of participantsPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
Parts 1 and 2: Percentage of Participants With GS-3583 Anti-drug Antibodies (ADAs) at Any Visit—33.333.300——————
SecondaryPart 1: Pharmacokinetic (PK) Parameter: AUCtau of GS-3583

AUCtau is defined as the area under the concentration versus time curve over the dosing interval where tau = 15 days.

Time frame:
Cycles 1 and 3, pre-dose, EOI; 2, 6 hours; Days 2, 3, 5, 8, 15 post Day 1 EOI; Day 15:Cycle 1:predose and EOI; 2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1; Infusion duration=60 minutes)
Reported as:
Mean · h*ng/mL
Part 1: Pharmacokinetic (PK) Parameter: AUCtau of GS-3583
h*ng/mLPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μg
Cycle 1—82100 ± 19900249000 ± 124000352000 ± 41300832000 ± 223000
SecondaryPart 1: PK Parameter: Cmax of GS-3583

Cmax is defined as the maximum observed plasma concentration.

Time frame:
Cycles 1 and 3,pre-dose,EOI;2, 6 hours;Days 2, 3, 5, 8, 15 post Day 1 EOI;Day 15:Cycle 1:predose and EOI;2 hours post EOI;Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1;Infusion duration=60 minutes)
Reported as:
Mean · ng/mL
Part 1: PK Parameter: Cmax of GS-3583
ng/mLPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μg
Cycle 1—643 ± 36.31860 ± 5622520 ± 2445800 ± 1460
SecondaryPart 1: PK Parameter: Tmax of GS-3583

Tmax is defined as the time to reach maximum observed plasma concentration (Tmax).

Time frame:
Cycles 1 and 3, pre-dose, EOI; 2, 6 hours; Days 2, 3, 5, 8, 15 post Day 1 EOI; Day 15:Cycle 1:predose and EOI; 2 hours post EOI; Cycle 3:336 hours and Day 24 post EOI (Cycle length for all cycles=28 days in Part 1; infusion duration=60 minutes)
Reported as:
Median · hours (h)
Part 1: PK Parameter: Tmax of GS-3583
hours (h)Part 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μg
Cycle 1—1.1 (1.0 to 1.1)2.0 (1.1 to 5.6)1.1 (1.1 to 2.0)1.7 (1.2 to 2.1)
SecondaryPart 2: Confirmed Objective Response Rate (ORR)

Confirmed ORR is defined as the percentage of participants who have achieved confirmed CR or PR according to RECIST V1.1 and assessed by the investigator. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
First dose date in Part 2 to End of Study (approximately 4.2 months)

No measurements were reported for this outcome.

SecondaryPart 2: Progression-free Survival (PFS)

PFS is defined as the time from first dose date until first date of disease progression (PD) or death from any cause, whichever comes first as measured per RECIST V1.1 as assessed by the investigator. Per RECIST V1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
First dose date in Part 2 to End of Study (approximately 4.2 months)

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Response (DOR)

DOR was defined as time of first response (CR or PR) per RECIST V1.1 as assessed by the investigator until the date of first documented disease progression or death, whichever comes first. Per RECIST V1.1, CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
First dose date in Part 2 to End of Study (approximately 4.2 months)

No measurements were reported for this outcome.

SecondaryPart 2: Overall Survival (OS)

Overall survival is defined as the time from randomization until death from any cause.

Time frame:
First dose date in Part 2 to End of Study (approximately 4.2 months)

No measurements were reported for this outcome.

SecondaryPart 2: Disease Control Rate (DCR)

DCR was defined as percentage of participants with a best overall confirmed response of CR or PR or stable disease. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
First dose date in Part 2 to End of Study (approximately 4.2 months)

No measurements were reported for this outcome.

SecondaryPart 2: PK Parameters: Cmax for GS-3583

Cmax is defined as the maximum observed serum concentration of drug.

Time frame:
Safety-run In:Cycles 1 and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, 15; Part 2 all arms:Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 60-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)

No measurements were reported for this outcome.

SecondaryPart 2: PK Parameter: Tmax for GS-3583

Tmax is defined as the time (observed time point) of the occurrence of Cmax.

Time frame:
Safety-run In: Cycles 1, and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, Day 15; Part 2: all arms: Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 6-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)

No measurements were reported for this outcome.

SecondaryPart 2: PK Parameter: AUCtau of GS-3583

AUCtau is defined as the area under the concentration versus time curve over the dosing interval.

Time frame:
Safety-run In: Cycles 1, and 3: Day 1, predose, EOI; 2, 6 hours, Days 8, Day 15; Part 2: all arms: Cycles 2 and 5: Day 1 predose, EOI and every odd cycles; 6-day FU; (Cycle length of all cycles = 21 days in Part 2; Infusion duration=60 minutes)

No measurements were reported for this outcome.

Adverse events

Collected over Up to 14.8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort 1: GS-3583 675 μg———
Part 1: Cohort 2: GS-3583 2000 μg3/3 (100%)2/3 (66.7%)3/3 (100%)
Part 1: Cohort 3: GS-3583 6000 μg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part 1: Cohort 4: GS-3583 12000 μg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part 1: Cohort 5: GS-3583 20000 μg2/4 (50%)1/4 (25%)4/4 (100%)
Part 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer Therapy———
Part 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer Therapy———
Part 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer Therapy———
Part 2: Randomized Expansion Cohort A: Combination Anticancer Therapy———
Part 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer Therapy———
Part 2: Randomized Expansion Cohort B: Combination Anticancer Therapy———
Most frequent serious events
Most frequent serious events
EventPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
Abdominal painGastrointestinal disorders—1/30/30/30/4——————
Large intestinal obstructionGastrointestinal disorders—1/30/30/30/4——————
Small intestinal obstructionGastrointestinal disorders—0/31/31/30/4——————
SepsisInfections and infestations—0/30/31/30/4——————
HyponatraemiaMetabolism and nutrition disorders—1/30/30/30/4——————
Cerebrovascular accidentNervous system disorders—1/30/30/30/4——————
Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps)—0/30/30/31/4——————
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPart 1: Cohort 1: GS-3583 675 μgPart 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgPart 2: Safety Run-In Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Safety Run-In Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort A: Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: GS-3583 + Combination Anticancer TherapyPart 2: Randomized Expansion Cohort B: Combination Anticancer Therapy
FatigueGeneral disorders—2/31/33/32/4——————
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)—3/31/30/30/4——————
Abdominal painGastrointestinal disorders—0/32/32/30/4——————
ConstipationGastrointestinal disorders—0/30/32/31/4——————
Bone painMusculoskeletal and connective tissue disorders—0/32/30/30/4——————
NauseaGastrointestinal disorders—1/31/31/32/4——————
ThrombocytopeniaBlood and lymphatic system disorders—0/30/31/30/4——————
Abdominal pain upperGastrointestinal disorders—0/30/31/30/4——————
AscitesGastrointestinal disorders—1/30/30/30/4——————
DiarrhoeaGastrointestinal disorders—0/31/30/31/4——————

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Part 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgTotal
<=18 years00000
Between 18 and 65 years01214
>=65 years32139
Age, Continuous
Age, Continuous(years)Part 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgTotal
Mean72 ± 1.263 ± 17.658 ± 15.370 ± 7.566 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgTotal
Female23016
Male10337
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgTotal
Hispanic or Latino02114
Not Hispanic or Latino31239
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White333312
More than one race00011
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Part 1: Cohort 2: GS-3583 2000 μgPart 1: Cohort 3: GS-3583 6000 μgPart 1: Cohort 4: GS-3583 12000 μgPart 1: Cohort 5: GS-3583 20000 μgTotal
United States333413
08

Study locations

4 sites
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • NEXT oncology
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Brody J, Thompson JA, Tolcher AW, Kuhne MR, Huang XR, et al. Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS3583, a FLT3 Agonist Fc Fusion Protein, in Patients With Advanced Solid Tumors [Poster TPS3147]. J Clin oncol 2021 June; 39 (15_suppl).
  • Tolcher AW, Brody J, Rajakumaraswamy N, Lakhani NJ, Kuhne MR, Trowe T, et al. Phase 1b study of GS-3583, a novel FLT3 agonist Fc fusion protein, in patients with advanced solid tumors. [Poster TPS2566]. J Clin oncol 2022 June; 40 (16_suppl).
  • Dauki AM, Jones A, Singh I, Rajakumaraswamy N, Qin A, et al. Population pharmacokinetics of GS-3583 in healthy volunteers and patients with advanced solid tumors [Poster II-083]. Clin Pharmacol Ther 2023 March; 113 (S5-S100).

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Nov 2022, 19 months.

Results were first posted in Sep 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Feb 10, 2021
StartActual
Mar 25, 2021
Primary completionActual
Nov 7, 2022
CompletionActual
Nov 7, 2022
Results first posted
Sep 3, 2024
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04747470
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Mar 25, 2021
Primary completion
Nov 7, 2022
Completion
Nov 7, 2022
Results posted
Sep 3, 2024
Last update
Sep 3, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zimberelimab · Docetaxel

Start the discussion